INTRODUCTION
Gastric cancer is the most prevalent cancer in Korea, and it ranks as one of the leading causes of cancer death, followed by lung cancer [1, 2] . Helicobacter pylori infection, diet, bile reflux, excessive cell proliferation, and DNA damage are known to be risk factors for gastric adenocarcinoma [3, 4] . Numerous other factors, such as histological features and clinical stage, have also been shown to play important roles in tumor development [5, 6] .
Cortactin (CTTN) regulates the actin cytoskeleton through its involvement in several processes, including cell motility, adhesion, polarization, contraction, and others [7] [8] [9] . The amplification of chromosome 11q13 has been reported in several human carcinomas along with increased expression of CTTN [9] . Overexpression of CTTN induces cell motility and migration, inhibits cell-cell adhesion, and accelerates tumor spreading [10] . CTTN is overexpressed in many types of human cancers, including esophageal squamous cell carcinoma, head and neck squamous cell carcinomas (HNSCC), colorectal, gastric, hepatocellular, breast, and ovarian cancers [11] [12] [13] [14] .
In some studies, overexpression of CTTN correlated with histological differentiation, T and N stage in gastric cancer, depth of invasion in colorectal cancer, as well as poor prognosis for patients with lymph node metastasis [15, 16] . However, direct evidence is still lacking to establish a relationship between CTTN overexpression and tumor progression and metastasis in gastric adenocarcinoma. The relationship between CTTN polymorphisms and susceptibility to gastric cancer is also unclear. Therefore, this study was aimed at investigating the association between the CTTN g.-9101C>T, g.-8748C>T, and g.72C>T polymorphisms and susceptibility to gastric cancer, to identify specific polymorphisms as potential risk factors.
METHODS
Peripheral blood samples were collected from 267 consecutive patients who were diagnosed with gastric cancer at Wonkwang University Hospital between June 2001 and August 2007. We collected blood sam ples from 533 healthy volunteers, which served as controls. Retrospectively, three single nucleotide polymorphisms (SNPs), CTTN g.-9101C> T, g.-8748C> T, and g.72C> T, and clinicopathologic data in the corresponding patients and controls, were analyzed to investigate the association of CTTN genetic polymorphisms with susceptibility to gastric cancer.
The stages of gastric cancer were sorted using the American Joint Committee on Cancer manual, seventh edition. Patients were divided by tumor depth into an early gastric cancer (EGC) group and an advanced gastric cancer (AGC) group, respectively. Patients were also divided based on the presence or absence of lymph node metastasis, into an LN (+) group and an LN (-) group, respectively. Clinicopathologic characteristics of gastric cancer patients are listed in Table 1 .
Analysis of CTTN polymorphisms
Genomic DNA extracted from the peripheral blood of members of each group was analyzed using the polymerase chain reaction-restriction fragment length polymorphism method for the CTTN g.-9101C> T, g.-8748C> T polymorphisms, and using the TaqMan method for the g.72C> T polymorphism. In gastric cancer patients, CTTN SNPs were analyzed using their peripheral blood collected before surgery.
The DNA samples used in the current study were provided by the Biobank of Wonkwang University Hospital, a member of the National Biobank of Korea; this Biobank is supported by the Ministry of Health and Welfare. The current study was approved by the Institutional Review Board of Wonkwang University Hospital (WKUH-1157), and written informed consent was obtained from all participants.
Polymerase chain reaction-restriction fragment length polymorphism
Each of the CTTN sequences containing the -9101C>T or -8748C>T polymorphic sites was partially amplified using the corresponding primer set (CTTN-PF1; 5'-TCCCAGGTGAG TACCCATGTGGT-3' and CTTN-PR1; 5'-TCGCGGCCAGGCGACGCC ACA-3'). An initial polymerase chain reaction (PCR) denaturation step was performed at 95 o C for 5 minutes, followed by Values are presented as mean ± standard deviation or number (%). a) TNM classification as per guidelines in American Joint Committee on Cancer 7th edition.
at 37 o C, respectively, and then separated on a 1.5% agarose gel and visualized under UV light with ethidium bromide. After restriction enzyme digestion, the PCR products of the sequences containing -9101C>T (630bp) and -8748C>T (630bp) took the form of two fragments, of 490 bp and 140 bp in length, respectively.
Taq-Man analysis
The assay reagents used for analysis of the g.72C>T (rs2298397) polymorphic site in the CTTN gene were designed by Applied Biosystems (Applied Biosystems, Foster City, CA, USA). The reagents consist of a 40× mix of unlabeled PCR primer and TaqMan MGB probes (FAM and VIC dye-labeled). The 10-mL reaction mix was optimized to work with 0.125 mL of 40× reagents, 5 mL of 2× TaqMan 
Statistical analysis
We determined whether the allelic distribution of the SNPs was consistent with the Hardy-Weinberg equilibrium using the chi-square test. The allele and genotype frequencies of these SNPs were compared between the patients and controls using the chi-square test or the Fisher exact test. Survival rates were calculated using the Kaplan-Meier method. P-values less than 0.05 were considered to indicate statistical significance.
RESULTS

Genotype and allele frequencies of the CTTN polymorphisms
The genotype frequencies of the CTTN g.-9101C>T polymorphism were 97.5% (TT), 2.5% (TC), and 0% (CC) in the patient group, and were 98.6% (TT), 1.4% (TC), and 0% (CC) in the control group. The genotype frequencies of the CTTN g.-8748C>T polymorphism were 93.2% (TT), 6.8% (TC), and 0% (CC) in the patient group, and were 94.2% (TT), 5.8% (TC), and 0% (CC) in the control group. The genotype frequencies of the CTTN g.72C>T polymorphism were 82.4% (CC), 17.2% (CT), and 0.4% (TT) in the patient group, and were 78.0% (CC), 20.1% (CT), and 1.9% (TT) in the control group. The genotype and allele frequencies of the CTTN g.-9101C>T, g.-8748C>T, and g.72C>T polymorphisms were not significantly different between the patient group and the control group (Table 2) .
Genotype and allele frequencies of the CTTN polymorphisms, compared among the EGC group, AGC group, and controls susceptible to gastric cancer
The genotype and allele frequencies of the CTTN g.-8748C>T, and g.72C>T polymorphisms were not different among the EGC, AGC, and control groups. However, the genotype and allele frequencies of the CTTN g.-9101C>T polymorphism were significantly different between the AGC group and the control group (P = 0.036 and P = 0.040, respectively) ( Table 3 ).
Genotype and allele frequencies of the CTTN polymorphisms among the LN (-) and LN (+) gastric cancer groups, and controls susceptible to gastric cancer
The genotype and allele frequencies of the CTTN g.-9101C>T, g.-8748C>T, and g.72C>T polymorphisms were not different among lymph node-negative, lymph node-positive, and control groups (Table 4) .
Relationship between the genotypes in the CTTN g.-9101C>T polymorphism and the survival time in patients with AGC
Clinicopathologic characteristics of 60 patients with advanced gastric adenocarcinoma based on the genotypes of CTTN g.-9101C>T polymorphism are listed in Table 5 and there was no different between the genotypes (Table 5) .
The 60 patients with AGC in the CTTN g.-9101C>T polymorphism were followed up for 5 years, and were divided into 3 groups based on the CTTN genotype. The group with a TC genotype had a significantly poorer prognosis than the group with a TT genotype (P = 0.020) (Fig. 1) .
DISCUSSION
The development of gastric cancer appears to be the result of a complex interaction between environmental and genetic factors. In particular, the frequency and the variety of genetic polymorphisms in gastric cancer patients seem to vary according to contributing factors, including genetic background and personal factors, which usually go together [3] [4] [5] [6] [7] [17] [18] [19] .
Various associations of polymorphisms with disease have been shown in many studies, enabled by the sequencing of the entire human genome and by recent developments in genetics. There has also been an explosion of information concerning natural genetic variations in the human genome, and their functional and clinical significance. This scientific progress allows us to delineate the complex role that genetic factors play in the onset and progression of common multifactorial diseases [20, 21] . The group with the TC genotype had a significantly poorer prognosis than the group with the TT genotype (P = 0.020). CTTN, cortactin. CTTN was initially identified as a tyrosine-phosphorylated protein in v-Src-infected chicken embryofibroblasts [22] . Subsequent cloning of the cDNA encoding CTTN revealed a novel protein with a unique domain structure. Structural predictions based on the amino acid sequence indicated that CTTN is comprised of several domains. At that time, little was known about its function, except that it binds to actin filaments, it has an Src homology (SH) 3 domain, and is phosphorylated in its C-terminus by an Src kinase [7] [8] [9] 23] .
CTTN contains a proline-rich region with c-Src tyrosine phosphorylation sites and a SH3 domain at the COOH terminus. It also contains an N-terminal acidic region that binds to the Arp2/3 complex. Phosphorylation binding sites and the SH3 domain are necessary for both the activation and the regulation of Arp2/3-complex-mediated branched actin assembly [7] [8] [9] 24] .
Resent research suggests that CTTN may regulate endocytosis of integrins and growth factor receptors, or secretion of proteases and extracellular matrix. These regulations have effects on cell motility, which is dependent on the cell context [25, 26] .
The CTTN gene was found to be identical to Ems1, a gene that is frequently overexpressed in breast and head and neck cancers, due to its presence in the 11q13 amplicon. 11q13 amplification has been frequently tied to a poor prognosis, with outcomes including associations with a higher pathological stage, lymph node and distant metastases, and a decreased survival rate [9] [10] [11] [12] [13] [14] [15] [16] .
Although many other genes are present within this amplicon, the consistent overexpression of CTTN in 11q13-amplified tumors, along with its ubiquitous presence in structures involved in cell motility, such as lamellipodia and invadopodia, have generated a great deal of interest in the role of CTTN in tumor invasion [9] [10] [11] [12] [13] [14] [15] [16] 27] .
In HNSCC patients, 30%-40% of tumors contain the 11q13 amplicon, and its presence clearly correlates with poor patient prognosis, including decreased survival [13] .
Of the many interesting genes, which are present in this amplicon, cyclinD1 and CTTN have been considered the best candidates for promoting tumor aggressiveness since, unlike many of the other genes in the amplicon, they are consistently overexpressed upon amplification [28] .
Chuma et al. [14] reported that overexpression of CTTN may play a role in the metastasis of hepatocellular carcinomas (HCC) by influencing cell motility, and that CTTN could be a sensitive marker for HCC with intrahepatic metastasis. Recent research has also shown that overexpression of CTTN is closely associated with a poor prognosis in patients affected by HCC caused by cancer embolus and metastasis [29] .
In colorectal cancer, Lee et al. [30] reported that the genotype and allele frequencies of the CTTN g.-8748C>T and g. 72C>T polymorphisms were not different between the colorectal cancer patient group and the control group, but that the genotype and allele frequencies of the CTTN g.-9101C>T polymorphism were significantly different between the lymph node-positive colorectal cancer group and the control group. These results show that the CTTN g.-9101C>T polymorphism may have an influence on lymph node-positive colorectal cancer.
At present, direct evidence is still lacking to establish a relationship among CTTN overexpression, tumor progression, and metastasis in gastric adenocarcinoma, and the relationship between CTTN polymorphisms and susceptibility to gastric cancer is unclear.
In our study, we successfully demonstrated that the genotype and allele frequencies of the CTTN g.-9101C>T polymorphism were significantly different between the AGC group and the control group, and that advanced gastric patients in the group with the TC genotype in the CTTN g.-9101C>T polymorphism had a significantly poorer prognosis than those in the group with the TT genotype.
These results show that there is an association between the specific CTTN polymorphism and the depth of invasion of the tumor in gastric cancer. Moreover, there is the possibility that the specific CTTN g.-9101C>T polymorphism present influences the susceptibility to AGC.
To our knowledge, this is the first report to evaluate the association between CTTN polymorphisms and the susceptibility to gastric cancer.
However, additional studies with large populations and many ethnic groups are needed to clarify the associations between the respective CTTN g.-9101C>T, g.-8748C>T, and g.72C>T polymorphisms and susceptibility to gastric cancer.
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